Skip to search formSkip to main contentSkip to account menu

Revlimid

Known as: Celgene brand of lenalidomide, Revimid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Novel oral immunomodulatory drug lenalidomide has been proven to have significant clinical activity in multiple myeloma (MM… 
2014
2014
In December, Celgene, of Summit, New Jersey, signed a deal potentially worth a whopping $3.3 billion for options on up to six… 
Review
2013
Review
2013
Today, multiple myeloma (MM) can be defined as a heterogenous disease composed of different clinical conditions. The differences… 
2008
2008
8587 Background: Typical stem cell mobilization regimens in MM include G-CSF alone or with high-dose cyclophosphamide. Given the… 
2004
2004
Le myelome multiple (MM) represente environ 1 % des cancers et 10‐12 % des hemopathies malignes. La mediane d’âge au diagnostic…